What Agenus’ BOT and BAL biomarker work reveals about rescuing immunologically cold tumors
Agenus’ AACR-IO biomarker data reframes inflammation as a key determinant in cold tumor immunotherapy. Find out why this could reshape checkpoint strategies.
Pharma & Biotech
Pharma & Biotech
Can Senhwa’s CX-5461 finally turn cold tumors hot in immunotherapy’s toughest challenge?
Senhwa Biosciences Inc. and BeOne Medicines have signed a clinical supply agreement to explore a novel drug combination aimed at treating hard-to-reach cancers. The collaboration will test Senhwa’s lead compound Pidnarulex (CX-5461), a G-quadruplex stabilizer, in combination with BeOne’s PD-1 inhibitor tislelizumab. The Phase 1b/2a clinical trial will enroll patients with advanced solid tumors, including